Company news
Longeveron Inc. news in 2024
Longeveron Inc.'s news releases, calls and decks from 2024, newest first.
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
December 1, 2024
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
November 10, 2024
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
November 3, 2024
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
October 28, 2024
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 26, 2024
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
October 13, 2024
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
October 6, 2024
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 2, 2024
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
August 4, 2024
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 27, 2024
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 17, 2024
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 16, 2024
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
July 9, 2024
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 7, 2024
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
June 17, 2024
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
June 16, 2024
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 10, 2024
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 2, 2024
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Longeveron Announces Board of Directors Planned Transitions
May 9, 2024
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
May 1, 2024
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
April 17, 2024
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
April 16, 2024
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 14, 2024
Longeveron Announces Closing of $5.2 Million Public Offering
April 10, 2024
Longeveron Announces Pricing of $5.25 Million Public Offering
April 7, 2024
Longeveron Announces 1-for-10 Reverse Stock Split
March 18, 2024
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
February 26, 2024
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
February 20, 2024
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
January 28, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (May 2024)
Investor deck · 24 slides · May 2024